Harold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.
Adjuvant Ribociclib/NSAI Yields iDFS Benefit in HR+/HER2– Early Breast Cancer
Adjuvant ribociclib plus aromatase inhibitors significantly improved invasive disease-free survival in early breast cancer, as shown in the NATALEE trial.
Cardiovascular Considerations in Breast Cancer Treatment and Survivorship
Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.
Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer
The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.
Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Analyzing Trials and Treatments in HER2+ Breast Cancer
Experts discuss various treatment options for patients with HER2-positive breast cancer, and which would benefit the most based on their characteristics.
Japan’s MHLW Receives sNDA for T-DXd Combo in Frontline HER2+ Breast Cancer
Data from the phase 3 DESTINY-Breast09 trial presented at the 2025 ASCO Annual Meeting formed the basis of the supplemental NDA.